Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies

Application of immunotherapeutic modalities changed paradigms in the treatment of hematologic malignancies, with regards to drug manufacturing, treatment protocols, short- and long-term toxicities. FDA-approved therapies, including blinatumomab, tisagenlecleucel, and axicabtagene ciloleucel, target...

Descripción completa

Detalles Bibliográficos
Autor principal: Jacoby, Elad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atlantis Press 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432394/
https://www.ncbi.nlm.nih.gov/pubmed/34595414
http://dx.doi.org/10.2991/chi.d.190219.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432394/
https://www.ncbi.nlm.nih.gov/pubmed/34595414
http://dx.doi.org/10.2991/chi.d.190219.001

Ejemplares similares